Utah Medical Products (UTMD) Liabilities and Shareholders Equity (2010 - 2026)

Utah Medical Products has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $124.4 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 1.52% year-over-year to $124.4 million; the trailing twelve-month figure through Mar 2026 stood at $489.7 million (down 2.99% YoY), and the FY2025 full-year result was $122.5 million, changed 0.0% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $124.4 million, up from $122.5 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $135.5 million in Q4 2023, with the low at $116.1 million in Q2 2022.
• Average Liabilities and Shareholders Equity over 5 years is $125.5 million, with a median of $123.9 million recorded in 2022.
• Year-over-year, Liabilities and Shareholders Equity increased 12.33% in 2023 and slipped 9.54% in 2025.
• Tracing UTMD's Liabilities and Shareholders Equity over 5 years: stood at $123.9 million in 2022, then grew by 9.35% to $135.5 million in 2023, then slipped by 9.54% to $122.5 million in 2024, then grew by 0.0% to $122.5 million in 2025, then gained by 1.5% to $124.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $124.4 million (Q1 2026), $122.5 million (Q4 2025), and $122.0 million (Q3 2025), per Business Quant data.

Peer Comparison